Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alaunos Therapeutics, Inc. (TCRT) filings document an early-stage biotechnology issuer with a developing small-molecule program, a legacy TCR-T oncology platform and a public-company capital structure. Form 8-K reports cover ALN1003 preclinical disclosures, material agreements, settlement matters, Nasdaq continued-listing notices, governance changes, director and officer transitions, and modifications to stockholder rights.
Registration statements, annual meeting reports and periodic-report references describe securities offerings, authorized common stock, stockholder voting results, operating and financial results, risk factors, and stockholders' equity used in Nasdaq compliance determinations.
Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. reported that director Michael Allen Jerman received a grant of 8,138 shares of common stock on 2026-07-23, valued at $1.92 per share. The shares were issued in lieu of board fees and increase his direct holdings to 23,759 shares.
Alaunos Therapeutics, Inc. CEO Holger Weis received a grant of 4,568 shares of common stock on 2026-07-23 at $1.92 per share, issued in lieu of net salary. After this compensation-related acquisition, he directly holds 21,120 common shares.
Robert W. Postma, a director of Alaunos Therapeutics, Inc., reported the acquisition of 8,463 shares of common stock on 23 July 2026 at $1.92 per share, described as shares issued in lieu of board fees. Following this grant, he holds 58,609 shares directly and additional indirect holdings of 24 shares through his spouse's IRA and 62,416 shares through WaterMill Asset Management Corp.
Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. director Jaime Vieser reported an equity compensation grant of 8,789 shares of common stock on 2026-07-23, valued at $1.92 per share and issued in lieu of board fees. Following this award, he holds 47,642 shares directly. The report also lists indirect holdings of 2,100 shares held by his children and 13,503 shares held by Brushwood LLC, where he serves as Manager.
Alaunos Therapeutics Chief Executive Officer Holger Weis received a stock grant as compensation. On June 30, 2026, he acquired 3,880 shares of Alaunos common stock at $2.26 per share in a grant issued in lieu of net salary. Following this award, he directly holds 16,552 common shares, and no derivative positions are reported in this filing.
Alaunos Therapeutics filed a current report describing new preclinical data for ALN1003, its investigational oral, non-hormonal, non-incretin metabolic candidate, from a 48-day diet-induced obesity mouse study. After adjusting for body fat percentage in an ANCOVA, ALN1003-treated animals showed significantly lower liver weight than controls, with p=0.000005 and confirmation using heteroscedasticity-robust HC3 standard errors.
The company notes this liver-weight signal is directionally consistent with earlier findings of lower liver injury enzymes, lower mean NAFLD Activity Scores, lower HOMA-IR, and favorable adipose endocrine biomarkers, but emphasizes the data are from non-GLP mouse studies that may not translate to humans. As of March 31, 2026, Alaunos reported cash and cash equivalents of about $0.354 million and plans to seek additional financing to continue operations and advance its obesity and metabolic disorders program.
Alaunos Therapeutics Chief Executive Officer Holger Weis reported a stock-based compensation transaction. On June 12, 2026, he acquired 7,761 shares of Alaunos common stock at $2.26 per share as a grant categorized as a "grant, award, or other acquisition." A footnote explains these shares were issued in lieu of net salary, indicating they are compensation rather than an open‑market purchase. Following this award, Weis directly holds 12,672 common shares of Alaunos Therapeutics.
Weis Holger reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. reported that Chief Executive Officer Holger Weis received a stock-based compensation grant. On May 22, 2026, he was issued 3,700 shares of common stock at $2.37 per share in lieu of net salary. Following this award, Weis directly holds 4,911 shares of Alaunos common stock. This transaction is classified as a grant or award rather than an open-market purchase or sale.
Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, its oral, non-hormonal small-molecule candidate for obesity and related metabolic disorders, based on two non-GLP diet-induced obesity mouse studies. Across these models, ALN1003 was associated with weight loss, favorable shifts in body composition, improved insulin-resistance biomarkers, adipose endocrine changes, and markers of improved liver health, including lower liver weight and enzymes and reduced steatosis scores in limited pathology samples.
The company emphasizes that all findings are from non-GLP animal studies, with important limitations and no established human safety or efficacy. Alaunos plans additional preclinical, pharmacology, formulation, and CMC work, as well as a computational chemistry program for next-generation compounds. As of March 31, 2026, it held about $0.354 million in cash and cash equivalents, with a cash runway extending into the second quarter of 2026, and intends to seek additional financing to continue operations and advance its obesity and metabolic disorders program.
Alaunos Therapeutics reported updated preclinical data for ALN1003, its investigational oral metabolic therapy for obesity and related metabolic disorders, from non-GLP diet-induced obesity mouse studies. ALN1003 was associated with significantly lower fasting insulin and HOMA-IR, along with higher adiponectin and an improved adiponectin-to-leptin ratio, suggesting a favorable insulin-resistance-related biomarker profile in these models.
Blinded liver histology in small pathology sets showed qualitative findings consistent with lower hepatic steatosis and lower mean NAS scores in ALN1003-treated animals versus controls. These results remain early, non-GLP, and preclinical, and ALN1003 has not been tested in humans. Alaunos also disclosed cash and cash equivalents of about $0.354 million as of March 31, 2026, with a cash runway extending into the second quarter of 2026 and plans to seek additional financing.